In this study we describe some biological effects of IL-34, a newly discovered cytokine. We show that 11-34 stimulates monocyte cell viability and directly modulates the number and function of monocytes and regulates myeloid cell growth and differentiation. Moreover, since IL-34 in mice is involved in osteoporosis, an antagonist of this cytokine could be beneficial for the treatment of this disease.Cytokines are immune-regulatory proteins (1-4) and they induce inflammation in vivo, based on recruitment of white blood cell population (5-7). These cytokines include IL-2, IL-4, IL-7, IL-9, IL-ll, IL-12, IL-13, IL-15 ... .IL-35 and Colony Stimulating Factors (CSFs) and many others. They are multifunctional proteins which have a role in both innate and adaptive immune responses (8-13) with an effect on proliferation, differentiation, inhibition, apoptosis and chemoattraction (14-16). In addition, cytokines are involved in and mediate many different diseases (17-18).The newly-characterized Interleukin-34 (IL-34) plays a central role in innate immunity and adaptive immunity, and is an important molecule for the communication between cells, tissues, and organs.Recently it has been reported that interleukin-34 (lL-34) stimulates monocyte viability but does not affect responses in a wide spectrum ofother assays (20)(21)(22)(23)(24)(25). In both in vitro and in vivo studies, IL-34 directly modulates the number and function of monocytes and regulates myeloid cell growth and differentiation. We believe that the immunological effects of IL-34 candidate this interleukin as an immunotherapeutic agent for the treatment of several different diseases (20,(26)(27)(28)(29)(30)(31)(32)(33)(34). To discover the receptor for IL-34, a collection ofextracellular domains oftrans-membrane proteins has been used which is a known cytokine receptor called colony-stimulating factor 1 receptor or macrophage colony-stimulating factor receptor